Valeda Light Therapy for Dry Macular Degeneration in Sarasota, FL

Valeda light therapy is an FDA-authorized, non-invasive treatment for intermediate dry macular degeneration. It uses specific wavelengths of red and near-infrared light to support retinal cell function.

Unlike injections or surgery, Valeda is delivered in the office using a specialized light device. The treatment is painless and does not require dilation or anesthesia.

Valeda is the first FDA-authorized device specifically indicated for intermediate dry AMD and represents a new category of treatment called photobiomodulation therapy.

Photobiomodulation, or PBM, is a non-invasive light therapy that uses specific wavelengths of red and near-infrared light to stimulate cellular activity. In the retina, PBM supports mitochondrial function, which helps improve energy production within retinal cells.

Mitochondria are responsible for producing energy that keeps cells functioning properly. In dry macular degeneration, cellular stress and inflammation contribute to gradual retinal cell loss. By enhancing mitochondrial performance, photobiomodulation may support cellular function and reduce oxidative stress in the retina.

PBM does not burn or damage tissue. It delivers low-level light energy that interacts with cells at a microscopic level. In the context of dry AMD, this therapy is designed to support retinal function and may improve visual performance in appropriately selected patients.

Valeda light therapy works by delivering specific wavelengths of red and near-infrared light to the retina to stimulate cellular function. This process, called photobiomodulation, enhances mitochondrial activity within retinal cells.

In dry macular degeneration, retinal cells become stressed and gradually lose function over time. By improving mitochondrial energy production, Valeda helps reduce inflammation, support cell survival, and improve overall retinal metabolism. This cellular support may slow the progression of disease and improve visual performance in certain patients.

Clinical trials have demonstrated improvements in visual acuity and functional vision in selected patients with intermediate dry AMD.

Valeda does not cure dry macular degeneration, but it provides a non-invasive way to support retinal health and potentially preserve central vision in patients with intermediate dry AMD.

Clinical studies suggest that Valeda light therapy can be effective for appropriately selected patients with intermediate dry macular degeneration. In the LIGHTSITE III clinical trial, patients who received regular photobiomodulation treatments demonstrated measurable improvements in visual acuity and reductions in drusen volume compared to untreated groups.

In clinical trials, some patients experienced an average improvement of approximately one line on the eye chart compared to untreated groups. The study also suggested a lower rate of progression toward geographic atrophy compared to untreated groups.

It is important to understand that results vary. Valeda does not cure dry macular degeneration, and it does not reverse advanced geographic atrophy. Its benefit appears strongest in patients with intermediate dry AMD who still have functioning central retinal cells.

When used in appropriate candidates and combined with regular monitoring, Valeda offers a non-invasive treatment option that may help maintain or improve visual function over time.

In clinical studies, some patients began to notice improvements in visual function within several months, with continued gains observed over longer follow-up periods.

Valeda light therapy is best suited for patients with intermediate dry macular degeneration who still have functioning central retinal tissue.

Patients who may benefit most from Valeda are those who:

• Have intermediate dry AMD
• Are experiencing gradual changes in central vision
• Do not have active wet AMD
• Still have viable retinal tissue in the macula

Valeda is not recommended for patients with advanced central geographic atrophy, significant central vision loss, or active wet macular degeneration.

A retina specialist determines candidacy through a comprehensive dilated exam and detailed retinal imaging. Careful evaluation ensures that treatment is offered to patients most likely to benefit from photobiomodulation therapy.

Valeda light therapy is typically delivered in treatment cycles. The standard protocol involves a series of nine sessions completed over three to five weeks, often scheduled three times per week.

After the initial series is completed, follow-up treatment cycles are usually repeated every four months. Ongoing therapy helps maintain the cellular benefits achieved during the first series and supports continued retinal health.

The exact schedule may vary slightly depending on your retinal findings and how your eyes respond to treatment. Your retina specialist will monitor your progress with imaging and adjust the timing of repeat cycles as needed.

Each Valeda light therapy session lasts approximately 20 minutes. The treatment is performed while you are seated comfortably, and no dilation or injections are required.

During the session, the device delivers controlled red and near-infrared light to the retina. The process is painless, and most patients experience little to no discomfort.

Because Valeda is non-invasive, there is no recovery time required after the session. Patients are typically able to resume normal activities immediately.

Medicare coverage for Valeda light therapy varies and is not universally guaranteed. Because Valeda is an FDA-authorized device-based treatment rather than a medication, coverage depends on individual Medicare plans and regional policy determinations.

Some patients may have partial coverage under Medicare Part B if the treatment is deemed medically necessary. Others may have out-of-pocket costs depending on their supplemental insurance and specific plan details.

Before beginning treatment, retina offices typically perform a benefits investigation to determine coverage and provide a clear estimate of potential costs. Patients are encouraged to discuss insurance questions with the practice so they can understand their financial responsibility before starting therapy.

The cost of Valeda light therapy can vary depending on your treatment plan and insurance coverage. Because Valeda is delivered in treatment cycles rather than as a single procedure, pricing is typically structured around a series of sessions.

Out-of-pocket costs depend on whether your insurance provides coverage and whether deductibles or copays apply. Some patients may pay entirely out of pocket, while others may receive partial reimbursement depending on their plan.

Before beginning therapy, your retina specialist’s office will review your benefits and provide a clear estimate of expected costs. Financial counseling is usually available so you can understand your options and make an informed decision before starting treatment.

Yes, most patients are able to drive immediately after a Valeda light therapy session. The treatment is non-invasive, does not require dilation, and does not involve injections or anesthesia.

Because Valeda does not blur vision or cause significant light sensitivity, there is typically no recovery time needed. Patients can return to normal daily activities, including driving, the same day.

If you feel uncomfortable or experience temporary visual changes, you may choose to have someone drive you home, but this is not usually necessary.